Acquisition of Nora Pharma Inc. (Details Narrative) |
12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
Apr. 22, 2024
USD ($)
|
Apr. 22, 2024
CAD ($)
|
Oct. 20, 2022
USD ($)
shares
|
Dec. 31, 2023
USD ($)
|
Dec. 31, 2023
CAD ($)
|
Jun. 30, 2026
USD ($)
|
Jun. 30, 2026
CAD ($)
|
Dec. 31, 2025
USD ($)
|
Oct. 20, 2022
CAD ($)
|
|
| Business Combination [Line Items] | |||||||||
| Earnout payable | $ 295,797 | $ 295,797 | |||||||
| Nora Pharma [Member] | |||||||||
| Business Combination [Line Items] | |||||||||
| Purchase price of shares | $ 18,860,637 | ||||||||
| Payments to acquire shares | $ 14,346,637 | ||||||||
| Stock issued for acquisition | shares | 185 | ||||||||
| Stock issued for acquisition, value | $ 4,514,000 | ||||||||
| Earnout liability expense, first installment | $ 1,036,500 | $ 1,426,914 | |||||||
| Earnout liability expense, second installment | $ 2,247,400 | $ 3,093,878 | |||||||
| Remaining earnout balance | $ 295,797 | $ 479,208 | |||||||
| Nora Pharma [Member] | Malek Chamoun [Member] | |||||||||
| Business Combination [Line Items] | |||||||||
| Earnout payable | $ 3,632,000 | $ 5,000,000 | |||||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of shares of stock issued during the period pursuant to acquisitions. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Value of stock issued pursuant to acquisitions during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|